Interacting Drugs |
Ketoconazole (systemic) vs Dabigatran Etexilate |
Security Level |
 |
Mechanism |
Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. |
Management |
Dabigatran dose reductions may be needed. According to Canadian labeling, dabigatran dose for prevention of venous thromboembolism post hip or knee replacement should be reduced to 150 mg/day in patients receiving amiodarone, verapamil, or quinidine. |
Ketoconazole (systemic) vs Dabigatran Etexilate
Post Review about Ketoconazole (systemic) vs Dabigatran Etexilate Click here to cancel reply.
Other Interactions of Ketoconazole (systemic)
Other Interactions of Dabigatran Etexilate
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.